STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT
In many ways, arterial hypertension and obesity determine the likelihood of a severe course and lethal outcomes in COVID-19. This fact justifies the expediency of an early use of drugs with a direct antiviral action, the analysis of their efficacy not only in the acute, but also in the postcovid per...
Saved in:
| Main Authors: | L. A. Balykova, O. A. Radaeva, K. Ya. Zaslavskaya, Yu. A. Kostina, M. S. Iskandyarova, E. V. Negodnova, V. V. Eremeev, L. F. Sabirov, E. V. Semeleva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2021-12-01
|
| Series: | Фармация и фармакология (Пятигорск) |
| Subjects: | |
| Online Access: | https://www.pharmpharm.ru/jour/article/view/981 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2024-03-01) -
Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
by: Abdullah Sayiner, et al.
Published: (2022-03-01) -
EFFICACY AND SAFETY OF SOME ETIOTROPIC THERAPEUTIC SCHEMES FOR TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19)
by: L. A. Balykova, et al.
Published: (2020-12-01) -
A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
by: Yu. V. Shevchuk, et al.
Published: (2025-02-01) -
Andrographis paniculata or favipiravir in Mild COVID-19: A randomized control trial
by: Rujipas Sirijatuphat, et al.
Published: (2025-08-01)